Electroceutical Targeting of the Autonomic Nervous System.


Author: Horn CC1,2,3, Ardell JL4,5, Fisher LE6,7

Affiliation: <sup>1</sup>Biobehavioral Oncology Program, UPMC Hillman Cancer Center , Pittsburgh, Pennsylvania.

<sup>2</sup>Department of Medicine, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania.

<sup>3</sup>Center for Neuroscience, University of Pittsburgh , Pittsburgh, Pennsylvania.

<sup>4</sup>University of California- Los Angeles (UCLA) Cardiac Arrhythmia Center, Los Angeles, California.

<sup>5</sup>UCLA Neurocardiology Research Program of Excellence, David Geffen School of Medicine , Los Angeles, California.

<sup>6</sup>Department of Physical Medicine and Rehabilitation, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania.

<sup>7</sup>Department of Bioengineering, University of Pittsburgh , Pittsburgh, Pennsylvania.
Conference/Journal: Physiology (Bethesda).
Date published: 2019 Mar 1
Other:
 Volume ID: 34   ,  Issue ID: 2   ,  Pages: 150-162   ,  Special Notes: doi: 10.1152/physiol.00030.2018.   ,  Word Count: 74  
    Autonomic nerves are attractive targets for medical therapies using electroceutical devices because of the potential for selective control and few side effects. These devices use novel materials, electrode configurations, stimulation patterns, and closed-loop control to treat heart failure, hypertension, gastrointestinal and bladder diseases, obesity/diabetes, and inflammatory disorders. Critical to progress is a mechanistic understanding of multi-level controls of target organs, disease adaptation, and impact of neuromodulation to restore organ function.



PMID: 30724129  DOI: 10.1152/physiol.00030.2018